| Source: |
| Type: |
| Adenosine triphosphate (ATP) is the source of energy for use and storage at the cellular level. Cellular ATP levels are critical for cell survival, and several reports have shown that reductions in cellular ATP levels can lead to apoptosis and other types of cell death in cancer cells, depending on the level of depletion. Adenosine triphosphate (ATP) is one of the main biochemical components of the tumor microenvironment (TME), where it can promote tumor progression or tumor suppression depending on its concentration and on the specific ecto-nucleotidases and receptors expressed by immune and cancer cells. Cancer cells, unlike normal cells, derive as much as 60% of their ATP from glycolysis via the “Warburg effect”, and the remaining 40% is derived from mitochondrial oxidative phosphorylation. |
| Glioblastoma is a fast-growing and aggressive brain tumor. |
| 5272- | 3BP, | The efficacy of the anticancer 3-bromopyruvate is potentiated by antimycin and menadione by unbalancing mitochondrial ROS production and disposal in U118 glioblastoma cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | Nor, | HEK293 |
| 1070- | IVM, | Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation |
| - | vitro+vivo, | GBM, | NA |
| 995- | MEL, | Melatonin Treatment Triggers Metabolic and Intracellular pH Imbalance in Glioblastoma |
| - | vitro+vivo, | GBM, | NA |
| 5125- | Sal, | Salinomycin induced ROS results in abortive autophagy and leads to regulated necrosis in glioblastoma |
| - | in-vitro, | GBM, | NA |
| 2410- | SIL, | Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vivo, | NA, | NA |
| 3138- | VitC, | The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity |
| - | in-vitro, | RCC, | RCC4 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Colon, | SW48 | - | in-vitro, | GBM, | U251 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:27 Cells:% prod#:% Target#:21 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid